Skip Navigation

Neuro-Oncology 2007 9(4):438-446; doi:10.1215/15228517-2007-026
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Maillo, A.
Right arrow Articles by Tabernero, M. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Maillo, A.
Right arrow Articles by Tabernero, M. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Society for Neuro-Oncology

Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone

Angel Maillo, Alberto Orfao, Ana B. Espinosa, José María Sayagués, Marta Merino, Pablo Sousa, Monica Lara and María Dolores Tabernero

Neurosurgery Service (A.M., M.M., P.S., M.L.) and Investigation Unit/IECSCYL (A.B.E., M.D.T.), University Hospital of Salamanca, 37007 Salamanca, Spain; and Department of Medicine, Cancer Research Center and Cytometry Service, University of Salamanca, 37007 Salamanca, Spain (A.O., J.M.S.)

Address correspondence to Angel Maillo, Servicio de Neurocirugía, Hospital Universitario de Salamanca, Paseo de San Vicente, 58, 37007 Salamanca, Spain (a_maillo{at}yahoo.es).


   Abstract

Tumor recurrence is the major clinical complication in meningiomas, and its prediction in histologically benign/grade I tumors remains a challenge. In this study, we analyzed the prognostic value of specific chromosomal abnormalities and the genetic heterogeneity of the tumor, together with other clinicobiological disease features, for predicting early relapses in histologically benign/grade I meningiomas. A total of 149 consecutive histologically benign/grade I meningiomas in patients who underwent complete tumor resection were prospectively analyzed. Using interphase fluorescence in situ hybridization, we studied the prognostic impact of the abnormalities detected for 11 different chromosomes, together with other relevant clinicobiological and histopathological characteristics of the disease, on recurrence-free survival (RFS) at 2.5, 5, and 10 years. From the prognostic point of view, losses of chromosomes 9, 10, 14, and 18 and del(1p36) were associated with a shorter RFS at 2.5, 5, and 10 years. Similarly, histologically benign/grade I meningiomas showing coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone displayed a higher frequency of early relapses. In fact, coexistence of -14 and del(1p36) in the ancestral tumor cell clone, together with tumor size, represented the best combination of independent prognostic factors for the identification of those patients with a high risk of an early relapse. Our results indicate that patients with large histologically benign/grade I meningiomas carrying monosomy 14 and del(1p36) in their ancestral tumor cell clone have a high probability of relapsing early after diagnostic surgery. These findings suggest the need for closer follow-up in this small group of patients.

Keywords: ancestral tumor cell clone, benign/grade I meningiomas, chromosomal abnormalities, cytogenetics, del(1p36), early recurrence, monosomy 14, prognostic factors

Received July 27, 2006; Accepted December 20, 2006


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
The OncologistHome page
M. D. Tabernero, A. B. Espinosa, A. Maillo, O. Rebelo, J. F. Vera, J. M. Sayagues, M. Merino, P. Diaz, P. Sousa, and A. Orfao
Patient Gender Is Associated with Distinct Patterns of Chromosomal Abnormalities and Sex Chromosome Linked Gene-Expression Profiles in Meningiomas
Oncologist, October 1, 2007; 12(10): 1225 - 1236.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.